{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:29:52Z","timestamp":1770344992576,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>We report on a 74-year-old female patient with a primary cutaneous CD20+, diffuse large cell B-cell lymphoma of the lower leg resembling a chronic non-healing leg ulcer. There was no evidence of systemic involvement on computed tomography (CT) scans of the chest, abdomen and pelvis; a slightly enlarged lymph node in the right groin showed dermatopathic lymphadenopathy on histology and immunohistochemistry. Involvement of the bone marrow and peripheral blood was ruled out by punch biopsy and fluorescent activated cell sorter (FACS) analysis of the blood, respectively. Therapeutic anti-CD20 monoclonal antibody rituximab was given at 375 mg m\u22122 i.v. once weekly for 7 weeks, without adverse effects, resulting in a minor improvement in the centre of the ulcerated tumour. Unfortunately, the response was not maintained, and after 7 weeks of treatment the patient started to develop new tumour lesions at the border of the ulcer. Local radiotherapy was started and combined photon and electron beam irradiation induced complete remission of the B-cell lymphoma.<\/jats:p>","DOI":"10.1046\/j.0007-0963.2001.04520.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T05:44:03Z","timestamp":1047361443000},"page":"144-147","source":"Crossref","is-referenced-by-count":35,"title":["Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer"],"prefix":"10.1093","volume":"146","author":[{"given":"A.","family":"Garbea","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dippel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hildenbrand","sequence":"additional","affiliation":[{"name":"Department of Pathology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bleyl","sequence":"additional","affiliation":[{"name":"Department of Pathology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Skin Cancer Unit (DKFZ) University Medical Center Mannheim, Ruprecht-Karls-University of Heidelberg, Theodor-Kutzer Ufer 1\u20133, 68135 Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goerdt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,1,1]]},"reference":[{"key":"2023072618420213400_b1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1524-4725.1984.tb00895.x","article-title":"Some statistical data, diagnosis, and staging of cutaneous B-cell lymphomas","volume":"10","author":"Burg","year":"1984","journal-title":"J Dermatol Surg Oncol"},{"key":"2023072618420213400_b2","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"2023072618420213400_b3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000418093","article-title":"Primary cutaneous follicular center cell lymphoma: clinical and histological aspects","volume":"19","author":"Pimpinelli","year":"1990","journal-title":"Curr Probl Dermatol"},{"key":"2023072618420213400_b4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.1996.14.2.549","article-title":"Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy","volume":"14","author":"Rijlaarsdam","year":"1996","journal-title":"J Clin Oncol"},{"key":"2023072618420213400_b5","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0190-9622(97)70090-2","article-title":"Primary cutaneous B-cell lymphoma: a clinically homogeneous entity?","volume":"37","author":"Pimpinelli","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2023072618420213400_b6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"key":"2023072618420213400_b7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/archderm.1996.03890350120023","article-title":"The morphologic spectrum of cutaneous B-cell lymphomas","volume":"132","author":"Kerl","year":"1996","journal-title":"Arch Dermatol"},{"issue":"Suppl. 2","key":"2023072618420213400_b8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/8.suppl_2.S29","article-title":"Primary B-cell lymphomas of the skin","volume":"8","author":"Kerl","year":"1997","journal-title":"Ann Oncol"},{"key":"2023072618420213400_b9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s001050050005","article-title":"Therapy of primary cutaneous B-cell lymphomas","volume":"51","author":"Zenahlik","year":"2000","journal-title":"Hautarzt"},{"key":"2023072618420213400_b10","first-page":"207","article-title":"The role of immunohistochemistry in the diagnosis of cutaneous lymphoma","volume":"13","author":"Smoller","year":"1997","journal-title":"Adv Dermatol"},{"key":"2023072618420213400_b11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA- approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"2023072618420213400_b12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"2023072618420213400_b13","first-page":"63","article-title":"Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies","volume":"12","author":"Maloney","year":"1998","journal-title":"Oncology (Huntingt)"},{"key":"2023072618420213400_b14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"2023072618420213400_b15","first-page":"1763\u2013","article-title":"Clinical status and optimal use of rituximab for B-cell lymphomas","volume":"12","author":"McLaughlin","year":"1998","journal-title":"Oncology (Huntingt)"},{"key":"2023072618420213400_b16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00000372-199906000-00011","article-title":"EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management","volume":"21","author":"Willemze","year":"1999","journal-title":"Am J Dermatopathol"},{"key":"2023072618420213400_b17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000478-200103000-00004","article-title":"Primary cutaneous large B-cell lymphoma. The relation between morphology, clinical presentation, immunohistochemical\u2423markers and survival","volume":"25","author":"Fernandez-Vasquez","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"2023072618420213400_b18","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"2023072618420213400_b19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Ann Oncol"},{"key":"2023072618420213400_b20","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"2023072618420213400_b21","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with\u2423low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"2023072618420213400_b22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2133.2000.03607.x","article-title":"Rituximab in cutaneous B-cell lymphoma: a report of two cases","volume":"143","author":"Sabroe","year":"2000","journal-title":"Br J Dermatol"},{"key":"2023072618420213400_b23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","article-title":"Intralesional therapy\u2423with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma","volume":"136","author":"Heinzerling","year":"2000","journal-title":"Arch Dermatol"},{"key":"2023072618420213400_b24","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"key":"2023072618420213400_b25","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"2023072618420213400_b26","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/1097-0142(19910501)67:9<2311::AID-CNCR2820670918>3.0.CO;2-0","article-title":"Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases","volume":"67","author":"Santucci","year":"1991","journal-title":"Cancer"},{"key":"2023072618420213400_b27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0360-3016(93)90251-P","article-title":"Radiotherapy of cutaneous B cell lymphomas: our experience in 31 cases","volume":"27","author":"Piccinno","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023072618420213400_b28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0167-8140(99)00089-4","article-title":"Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases","volume":"52","author":"Kirova","year":"1999","journal-title":"Radiother Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/146\/1\/144\/50968558\/bjd0144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/146\/1\/144\/50968558\/bjd0144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:45:45Z","timestamp":1690397145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/146\/1\/144\/6634383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2002,1,1]]},"published-print":{"date-parts":[[2002,1,1]]}},"URL":"https:\/\/doi.org\/10.1046\/j.0007-0963.2001.04520.x","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2002,1,1]]},"published":{"date-parts":[[2002,1,1]]}}}